2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13052
    SB-737050A 583045-76-5 98%
    SB-737050A is a potent 5-HT6 antagonist to prevent relapse into addiction.
    SB-737050A
  • HY-13486
    TAU-IN-1 1383373-65-6 98%
    TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases.
    TAU-IN-1
  • HY-13709
    Gantacurium chloride 213998-46-0 98%
    Gantacurium is an ultrashort-acting, nondepolarizing neuromuscular blocking agent that is degraded by nonenzymatic binding to L-cysteine under physiological conditions. Gantacurium causes a decrease in mean arterial pressure and an increase in heart rate.
    Gantacurium chloride
  • HY-13710
    Dimethindene 5636-83-9 98%
    Dimethindene is a potent, selective histamine H1 antagonist. Dimethindene impairs cutaneous wound healing (WH). Dimethindene can block K+ currents.
    Dimethindene
  • HY-13736
    Quinagolide 87056-78-8 98%
    Quinagolide (CV205-502) is a non-ergot dopamine D(2) receptor agonist that promotes dopamine activity. Quinagolide has shown effectiveness in modulating endocrine function, particularly in inhibiting disorders associated with dopamine deficiency. Quinagolide is used to suppress hyperprolactinemia and corresponding clinical symptoms, showing good efficacy. Quinagolide's biological activity enables its use as an important research compound in drug isolation and analysis.
    Quinagolide
  • HY-14129
    CP 316311 175139-41-0 98%
    CP 316311 is a potent and selective CRF1 receptor antagonist with an IC50 value of 6.8 nM.
    CP 316311
  • HY-14132
    BMS-665053 1173435-64-7 98%
    BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM).
    BMS-665053
  • HY-14148
    Renzapride hydrochloride 109872-41-5 98%
    Renzapride hydrochloride is a benzamide that inhibits irritable bowel syndrome and has antagonistic activity at 5-HT(3) receptors and agonistic activity at 5-HT(4) receptors. Renzapride hydrochloride also exhibits antagonistic activity at 5-HT(2B) receptors and has a certain affinity for 5-HT(2A) and 5-HT(2C) receptors.
    Renzapride hydrochloride
  • HY-14154
    THRX-194556 886579-13-1 98%
    THRX-194556 is a 5-HT4 receptor agonist. THRX-194556 can be used to study gastrointestinal functional disorders and Alzheimer’s disease.
    THRX-194556
  • HY-14160
    CB2 receptor agonist 7 871819-90-8 98%
    CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability.
    CB2 receptor agonist 7
  • HY-14202
    Lazabemide hydrochloride 103878-83-7 98%
    Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide  inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.
    Lazabemide hydrochloride
  • HY-14222
    UMB24 1033-69-8 98%
    UMB24 is a potent antagonist of σ2 receptor, with Ki values of 170 nM anf 322 nM for σ2 receptor and σ1 receptor, respectively. UMB24 attenuats cocaine-induced convulsions and locomotor activity, but not lethality.
    UMB24
  • HY-14223
    SM-21 155058-71-2 98%
    SM-21 is a derivative of R-(+)-hyoscyamine with potent antinociceptive and cognitive enhancing activities. SM-21 works by affecting the release of acetylcholine.
    SM-21
  • HY-14225
    BMS-764459 1188407-45-5 98%
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer.
    BMS-764459
  • HY-14226
    LIMK-IN-3 1116570-97-8 98%
    LIMK-IN-3 (Compound 33) is a LIMK2 inhibitor (IC50: 1.2 nM). LIMK-IN-3 can be used for glaucoma research.
    LIMK-IN-3
  • HY-14232
    TTA-A8 1146395-46-1 98%
    TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep.
    TTA-A8
  • HY-14312
    A85380 161416-98-4 98%
    A 85380 is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 exhibits selectivity for the α4β2 nAChR subtypes. A 85380 has a broad-spectrum analgesic profile.
    A85380
  • HY-14314
    ABT-418 147402-53-7 98%
    ABT-418 is a selective neuronal nicotinic acetylcholine receptor ligand with activity in improving spatial memory. ABT-418 administered before training can significantly reduce the spatial discrimination deficit caused by ventricular damage. ABT-418 is considered to be a potential treatment for attention deficit disorder.
    ABT-418
  • HY-14316
    Tebanicline 198283-73-7 98%
    Tebanicline, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.
    Tebanicline
  • HY-14330
    ABT-724 70006-24-5 98%
    ABT-724 is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM). ABT-724 has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile.
    ABT-724
Cat. No. Product Name / Synonyms Application Reactivity